Categories Uncategorized

Oregon Psilocybin Panel Joins Harvard to Study Psychedelic History

Researchers cleared by the Oregon Psilocybin Advisory Board will be working with Harvard Law School to study the culture and history of psychedelics. The aim of this new research project is to help inform legislative efforts in other states where psychedelics reform is being pursued.

In an interview, Mason Marks, director of Harvard’s Psychedelics Policy Center, stated that Oregon was one of the few states exploring the regulation of psilocybin services, adding that the project would help inform decision making. Marks is also a member of Oregon’s Psilocybin Advisory Board.

The panel, whose objective is to advise on the implementation of a legal psilocybin therapy program, released a report in July that reviewed studies on psilocybin. The report had concluded that psilocybin held significant therapeutic value for various mental health conditions, having demonstrated its effectiveness in decreasing anxiety and depression as well as some life-threatening conditions.

This new project will cover a lot more ground and will take about six months to complete. The researchers tasked with producing the comprehensive report will examine how psilocybin prohibition has impacted marginalized communities and how reform laws in the state of Oregon could affect the communities. The research proposal states that the project will only analyze and review existing research and notes that potential sources of data include narrative descriptions of psilocybin use, psychological and medical literature from the mid-20th century, bioethics literature, religious scholarship, anthropology literature, historical information on the use of psilocybin by indigenous communities, legal scholarship, legislative materials and public health data.

However, before any recommendations included in this comprehensive report are submitted to Oregon Health Authority regulators for consideration, they will have to be approved by the board.

In the interview, Marks added that it was important to include the practices and views of Indigenous communities as their ways were the foundation of the psychedelic industry. He explained that some cultures had used psychedelic substances such as psilocybin for centuries or even a few millennia, noting that this made them authorities in the psychedelics space and, as such, their expertise should be respected as well as acknowledged.

The report, which has been christened the Ethical Legal and Social Implications Report, will also cover how various jurisdictions have reformed laws that govern psilocybin, how the entheogenic substance could affect overdose and addiction rates, what community-based rituals have been established around the entheogen, how cultural attitudes towards psilocybin have changed over time and how the psychedelic affects communities.

The emergence of institutions giving attention to psychedelic policy and law matters is a good development since it complements the work being done by companies such as Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) as they seek to discover medicinal formulations made from various psychedelic compounds.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…

15 hours ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

4 months ago